Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...

Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line ...

Jazz’s Ziihera and BeOne’s Tevimbra plus chemotherapy led to what Truist Securities dubbed one of the strongest overall ...

At the San Antonio Breast Cancer Symposium (SABCS), investigators outlined the rationale and design of the ERADICATE, a first ...

Recent trials highlight T-DXd's superior efficacy and manageable toxicity in treating high-risk HER2-positive breast cancer, reshaping treatment strategies.

The current study -- HERIZON-GEA-01 -- was designed before the data from KEYNOTE-811 was revealed. That trial showed that ...

Highlights in ER-positive breast cancer from SABCS 2025 include key metastatic and early-stage trial results from AMBRE, ...

Zymeworks reported positive Phase 3 results from the HERIZON-GEA-01 trial of its engineered HER2-targeted antibody Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without PD-1 ...

The latest update is out from Abpro Holdings ( (ABP) ).

The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

If you or someone you love has HER2+ breast cancer, you’ll have a lot of questions. What will treatment look like? Will doctors be able to cure the cancer? How will it affect your quality of life? One ...